Table 2. Chemotherapy drugs and doses used in this study.

Drug	Concentrations used in this study	Published human peak intratumour or plasma concentrations
Soluble TRAIL	1 μg ml−1 100 ng ml−1	Not reported
F-LZ-TRAIL	100 ng ml−1 10 ng ml−1	Not reported
Superkiller TRAIL	100 ng ml−1	Not reported
Anti-DR5	3 μg ml−1 0.3 μg ml−1	Not reported
Cisplatin	54 μg ml−1 5.4 μg ml−1	Peak tumour concentration after embolisation was 54 μg ml−1, after perfusion was 11.4 μg ml−1 (Tegeder et al, 2003). Peak plasma concentrations ranged from 1.5 μg ml−1 (Riva et al, 2000; Urien et al, 2005) to around 4 μg ml−1 (Siegel-Lakhai et al, 2005; Watanabe et al, 2003)
Carboplatin	44 μg ml−1 4.4 μg ml−1	Peak glioma concentration was 13 μg ml−1, peak plasma concentration was 44 μg ml−1 (Whittle et al, 1999)
CCNU	9 μg ml−1 900 ng ml−1 90 ng ml−1	Peak plasma concentration of active metabolites was reported to be 9 μg ml−1 (Lee et al, 1985) or 1–2 μg ml−1 (Kastrissios et al, 1996)
Temozolomide	13.7 μg ml−1 1.37 μg ml−1	Peak plasma concentration was 13.7 μg ml−1 (Brada et al, 1999)
Etoposide	10.5 μg ml−1 1.05 μg ml−1	Peak tumour concentration was 1.04–4.80 μg g−1. Peak plasma concentration was 7–10.5 μg ml−1 (Kiya et al, 1992)
Vincristine	40.4 ng ml−1 4 ng ml−1	Peak plasma concentration was 40.5 ng ml−1 but rapidly decreased to 5 ng ml−1 (Groninger et al, 2005)
Procarbazine	540 ng ml−1 54 ng ml−1	Peak plasma concentration was 540 ng ml−1 (He et al, 2004)